• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Ockham acquires Nexus Oncology, expanding clinically and geographically

Ockham acquires Nexus Oncology, expanding clinically and geographically

February 13, 2012
CenterWatch Staff

Two small but powerful oncology-focused CROs are now one. Ockham Development Group of Cary, N.C., has acquired Nexus Oncology of Edinburgh, Scotland. 

Terms of the cash-and-stock deal were undisclosed. James Baker, Ockham’s CEO, said Nexus comes with a stable book of business and an institutional investment partner. Twelve-year-old Nexus has 120 employees across Scotland, Poland, France, Germany, Sweden, Switzerland, Hungary, Belgium and Spain, in addition to Canada and the U.S.

Ockham had 175 employees before the acquisition and operated primarily in the U.S., with satellite offices in India and the U.K. 

Nexus founder Clare Wareing will stay as chief scientific officer. For now, Nexus Oncology will be known as Nexus Oncology, an Ockham Company. But Baker said by yearend Ockham will make a final decision on the combined entity’s name.

Ockham launched in 1986 as ASG, a specialty staffing company focusing primarily on IT. Over time, it began working with pharma companies, providing CRAs, data managers, statistical programmers and biostatisticians, and eventually offering functional service provider (FSP) services to companies working on cancer drugs. In 2009, said Baker, the company acquired five-year-old Ockham, a “distressed” full-service CRO with 60 employees. The company stayed with the market segment Ockham had been serving: emerging biotech and pharma companies seeking help with phase I and II trials. 

Ockham and Nexus both compete with other small, oncology-focused CROs including Novella, Aptiv and Premier, said Baker. “The small trials we work on require a certain amount of leadership, and the large guys can’t do that as efficiently as we do,” he said. “As a result, we’ve created this nice niche where, at the end of the day, we’ve become known as one of the top five early-stage oncology CROs.”

Ockham also plans to use the acquisition to expand its FSP into clinical, which is Nexus’ specialty. 

 

By Suz Redfearn

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing